| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6102254 | TARO | Pharmaceutical compositions in semisolid form and a device for administration thereof |
Mar, 2013
(11 years ago) | |
| US5881926 | TARO | Pharmaceutical compositions in semisolid form and a device for administration thereof |
Mar, 2016
(8 years ago) | |
| US6071523 | TARO | Spill resistant pharmaceutical compositions in semi-solid form |
Jun, 2018
(5 years ago) | |
| US6656482 | TARO | Spill resistant pharmaceutical system |
Jun, 2018
(5 years ago) | |
| US6399079 | TARO | Spill resistant pharmaceutical compositions in semi-solid form |
Jun, 2018
(5 years ago) | |
| US7799331 | TARO | Oral suspension of prednisolone acetate |
Oct, 2028
(4 years from now) | |
Flo-Pred is owned by Taro.
Flo-Pred contains Prednisolone Acetate.
Flo-Pred has a total of 6 drug patents out of which 5 drug patents have expired.
Expired drug patents of Flo-Pred are:
- US6102254
- US5881926
- US6071523
- US6656482
- US6399079
Flo-Pred was authorised for market use on 17 January, 2008.
Flo-Pred is available in suspension;oral dosage forms.
Flo-Pred can be used as treatment of allergic reactions.
The generics of Flo-Pred are possible to be released after 11 October, 2028.
Drugs and Companies using
PREDNISOLONE ACETATE ingredient
Market Authorisation Date:
17 January, 2008Treatment:
Treatment of allergic reactionsDosage:
SUSPENSION;ORAL
More Information on Dosage
FLO-PRED family patents
